Back to Search Start Over

ATF4-dependent heme-oxygenase-1 attenuates diabetic nephropathy by inducing autophagy and inhibiting apoptosis in podocyte

Authors :
Shizhu Yuan
Xudong Liang
Wenfang He
Mingzhu Liang
Juan Jin
Qiang He
Source :
Renal Failure, Vol 43, Iss 1, Pp 968-979 (2021)
Publication Year :
2021
Publisher :
Taylor & Francis Group, 2021.

Abstract

Aim Podocyte injury plays an important role in diabetic nephropathy (DN), yet the underlying molecular mechanisms of podocyte injury in DN is not clear. Here, we investigated the role of activating transcription factor 4 (ATF4) and HO-1 in DN-induced podocyte injury. Methods Protein expression was measured by western blotting (WB) and immunofluorescence. Cellular apoptosis was quantified by flow cytometry. ATF4 siRNA knockdown and HO-1 overexpression in podocyte were employed to evaluate the role of ER stress in DN-induced apoptosis and autophagy response. Urinary protein levels, nephrin expression, serum creatinine and BUN were evaluated and glomerulosclerosis was quantified by Periodic Acid-Schiff staining. Results Expression of ATF4 was increased in podocytes exposed to serum from DN mice. ATF4 knockdown enhanced DN-induced podocyte apoptosis. HO-1 overexpression reduced the decline of DN-induced podocyte autophagy and inhibited apoptosis and the beneficial effects of HO-1 overexpression in DN were blocked by ATF4 knockdown. The diabetic mice were significantly ameliorated by HO-1 agonist hemin treatment. Conclusions ATF4 induces autophagy by enhancing the expression of HO-1, and inhibits podocyte apoptosis in DN. Treatment with the HO-1 agonist reduced proteinuria, apoptosis, and enhanced autophagy response, and thus improved renal function in DN mice.

Details

Language :
English
ISSN :
0886022X and 15256049
Volume :
43
Issue :
1
Database :
Directory of Open Access Journals
Journal :
Renal Failure
Publication Type :
Academic Journal
Accession number :
edsdoj.fa4bc29289094e20b1bb16f23ef65f97
Document Type :
article
Full Text :
https://doi.org/10.1080/0886022X.2021.1936040